Analysts Expect Aileron Therapeutics Inc (ALRN) Will Announce Earnings of -$0.50 Per Share

Equities research analysts expect that Aileron Therapeutics Inc (NASDAQ:ALRN) will report ($0.50) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aileron Therapeutics’ earnings, with estimates ranging from ($0.62) to ($0.39). Aileron Therapeutics reported earnings per share of ($0.47) during the same quarter last year, which suggests a negative year over year growth rate of 6.4%. The firm is scheduled to issue its next quarterly earnings results on Monday, April 1st.

According to Zacks, analysts expect that Aileron Therapeutics will report full year earnings of ($2.27) per share for the current year, with EPS estimates ranging from ($2.37) to ($2.17). For the next year, analysts anticipate that the firm will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.24) to ($1.63). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.08.

Several equities analysts have recently commented on ALRN shares. Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 13th. ValuEngine raised shares of Aileron Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new position in Aileron Therapeutics in the first quarter worth about $151,000. Paloma Partners Management Co bought a new position in Aileron Therapeutics in the second quarter worth about $140,000. Renaissance Technologies LLC bought a new position in Aileron Therapeutics in the third quarter worth about $137,000. Bridgeway Capital Management Inc. lifted its holdings in Aileron Therapeutics by 78.6% in the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Parkwood LLC bought a new position in Aileron Therapeutics in the third quarter worth about $149,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ALRN stock traded down $0.01 during trading hours on Friday, hitting $2.05. 73,600 shares of the company were exchanged, compared to its average volume of 56,949. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.23 and a current ratio of 4.23. Aileron Therapeutics has a one year low of $1.75 and a one year high of $11.35. The stock has a market capitalization of $30.38 million, a price-to-earnings ratio of -1.16 and a beta of 0.04.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Read More: How to read a candlestick chart

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply